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Abstract
Background Patients may recalibrate internal standards when
faced with a serious diagnosis or neurological deficits. This
so-called response shift is important to understand in longitu-
dinal health-related quality of life (HRQoL) data, but this is
not quantitatively assessed in glioma patients.
Methods Patients with gliomas were eligible for this HRQoL
study. We used EuroQol-5D 3 L to assess generic HRQoL
with assessment preoperatively and at 6 months postopera-
tively. At time of follow-up, patients scored how they consid-
ered their baseline HRQoL in retrospect using the same ques-
tionnaire (Bthen-test^).
Results Seventy-three patients were enrolled between January
2013 and September 2015. With the then-test approach, the
mean EQ-5D 3 L index was similar compared to baseline
(0.77, mean difference 0.01, 95% CI −0.57 to 0.07, p =
0.82). Also, then-test and baseline VAS score were similar
(mean difference 0, 95% CI −7 to 7, p = 0.97). However, a
0.10–0.13 difference from baseline was observed in patients
that improved or deteriorated in HRQoL at follow-up accord-
ing to the then-test EQ-5D 3 L index value. The direction of
change as observed from the then-test was similar to the di-
rection of clinical change, reducing the impact of any HRQoL
change from baseline to follow-up.
Conclusions On average, we observed no response shift using
EQ-5D 3 L in the selection of glioma patients able to participate
at 6months after surgery. However, following change inHRQoL
at follow-up, response shift seems to reduce the effects of
HRQoL changes by lowering of internal standards in patients
that deteriorate and raising the standards in patients that improve.
Keywords Glioma . Neurosurgery . Quality of life . Brain
neoplasm . Surgical management
Introduction
Research on health-related quality of life (HRQoL) in glioma
patients is gaining interest [14, 18, 22]. However, so-called
response shift is frequently considered to interfere with inter-
pretation of longitudinal HRQoL data [11, 14, 18]. Response
shift refers to the phenomenon where patients score better
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because over time they adapt to a new situation; for instance, a
handicap or an illness [17, 18]. It is considered to involve
elements of recalibration of internal standards, change in pri-
orities and/or a different view upon the concept of HRQoL [3,
8, 27]. In patients with gliomas all these elements may change
when faced with neurological deficits or being diagnosed with
a life-threatening illness [18].
Thus, such recalibration may therefore affect longitudinal
HRQoL data and interpretation of results, but unless assessed
directly it is impossible to detect if a recalibration has occurred
[3]. Themost common approach to study response shift is the so-
called Bthen-test approach^ where respondents retrospectively
score how they at time of follow-up consider their earlier or
baseline HRQoL in the light of their new situation [17, 25, 27].
In a meta-analysis from 2006, the effect sizes of response
shift were found to be small, with the largest effect sizes de-
tected for fatigue and global HRQoL [25]. Even though re-
sponse shift is known to occur in cancer patients [8, 9, 17, 18],
we have not found response-shift studies in glioma patients.
Searching for clinically relevant subgroups that could exhibit
response shift is also indicated.
In this project we aimed to prospectively study the direc-
tion and magnitude of response shift in glioma patients using a
global, generic HRQoL measure. Further, since response shift
is most pronounced in the presence of a trigger [2] (i.e. less
likely to occur in patients with stable condition), we explore




All adult patients (≥18 years old) that underwent surgery for
glioma at St. Olavs University Hospital, Trondheim, Norway,
in the period from January 2013 through September 2015
were eligible for inclusion in this study. In this period 210
patients with glioma underwent a neurosurgical procedure of
biopsy or resection. As shown in the flow-chart (Fig. 1), we
included in total 73 patients that had both a self-reported base-
line assessment and a self-reported postoperative assessment
at 6 months with the renewed retrospective scoring of their
baseline HRQoL.
All included patients had histopathological diagnosis of
WHO grade II-IV glioma confirmed by a neuropathologist
according to the 2007 WHO classification [19].
Euroqol 5D 3L
The EuroQol 5D 3L (EQ-5D 3L) is a generic measure of
health-related QoL developed by the EuroQol Group [28].
The EQ-5D 3L has been validated in a Norwegian normal
population [21]. The questionnaire has been applied to a wide
range of health conditions and treatments.
In EQ-5D 3L, five dimensions of HRQoL are scored: mo-
bility, self-care, usual activities, pain/discomfort and anxiety/
depression, with three possible answers to each dimension, i.e.
‘no problem’, slight problem’ or ‘major problem’. This results
in the 243 different possible health states, which are trans-
formed into an index value based on a large survey in the
UK population [6]. EQ-5D 3L index value is from –0.594 to
1, where 1 corresponds to perfect health, and 0 to death.
Negative values are considered to be worse than death. The
questionnaire also contains a visual analogue scale (VAS),
reflecting the global health state from 0 (worst possible score)
to 100 (best possible score).
We chose to use EQ-5D 3L due to the simplicity of the
instrument, to enhance patient perception and perhaps also
compliance. We have previously demonstrated that EQ-5D
3L index value shows good correlation to Karnofsky
Performance Scale (KPS) in patients with gliomas and is re-
sponsive to new neurological deficits which is highly relevant
in this patient group [15]. Further, we have found the minimal
clinically important change (MIC) to be approximately 0.13–
0.15 [22]. In this study we decided a priori that 0.15 was the
minimum magnitude of change necessary to be a clinical im-
portant change.
Data collection
Our routine has been that patients provided written informed
consent and filled out the EQ-5D 3L questionnaire 1–3 days
before surgery. The operating surgeon scored preoperative
KPS prospectively on admission. Patient follow-up by a study
nurse was scheduled at 6 months postoperatively to allow
recovery from transient surgically induced deficits. At
6 months, patients undergoing radiotherapy had also had time
for recovery; however, tumour progression/recurrence may,
on the other hand, occur.
Data were collected from the hospital’s electronic patient
charts. Patient characteristics and preoperative status includ-
ing Charlson comorbidity index [5], KPS [16] and eloquence
in tumour location [24] were registered. Complications were
scored according to the classification system proposed by
Landriel Ibañez and co-workers [10]. Tumour volumes and
resection grades were determined from preoperative and early
postoperative magnetic resonance imaging (MRI) volumes
using an ellipsoid model (4л × r3/3) where gross total resection
(GTR) was defined as <0.175 cm3 residual tumour tissue on
the early (<72 h) postoperative 1.5-Tor 3.0-TMRI scans; both
techniques previously described by others [26]. If the tumour
had a smaller contrast-enhanced region being surrounded by a
larger region with T2/FLAIR abnormalities believed to be
glioma and not oedema the entire tumour was measured, and
not only the contrast-enhancing part. For non-contrast-
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enhancing gliomas, the T2/FLAIR images were used for vol-
ume assessment.
Response shift
To assess response shift, we used a pre-test/post-test design
with a then-test [29]. The patients were asked to score their
baseline ratings of the five EQ-5D 3L domains and the VAS
score immediately after the post-test assessment at 6 months
follow-up. The research nurse emphasised that the intention of
the retrospective test was not to remember and copy their
answers at baseline but to provide a renewed baseline
HRQoL as they now would consider it in retrospect (then-
test). According to this method, patients use their new internal
standards in the then-test. The mean difference between the
then-test and prospective baseline test was then calculated to
provide the recalibration response shift effect, while the mean
difference between the then-test and the post-test was
210 patients with glioma 
eligible for inclusion 
36 patients without informed consent 
Too ill to answer= 3 
Unwillingness to participate = 16 
Cognitive impairment = 3 
Language problems = 3 
Administrative failure = 11 
174 patients gave their 
informed consent to 
participate in the study 
2 patients with preoperative proxy-
assessment excluded 
172 patients with self-
reported HRQoL-data at 
baseline 
42 patients without follow up 
6 patients not responding 
 1 patient with language problem 
 1 patient too ill to answer 
 8 patients withdrawal 
 26 patients dead 
106 patients with self-
reported HRQoL-data at 
follow up
24 patients with postoperative 
proxy-assessment excluded
33 patients without thentest (too 
burdensome)
73 patients with thentest 
included in the study 
Fig. 1 Flow chart
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calculated to provide a better estimate of the adjusted time
effect (i.e. the true change).
Statistical analysis
To analyse data and to create graphs we used the software
package SPSS (version 21.0; SPSS, Chicago, IL, USA). Q-
Q plots were used to test if data were normally distributed.
When analysing changes in EQ-5D 3L (e.g. before and after
surgery) a paired sample t-test was used. Comparisons of con-
tinuous data were done with independent samples t-test.
Categorical data were analysed with Pearson’s chi-squared
test. A p value ≤0.05 was considered statistically significant.
Results
Baseline and surgical characteristics are summarised in
Table 1. In 43 patients (59%) the surgery was a primary oper-
ation. The histopathology revealed a diffuse low-grade glioma
in 26 patients (36%) and a high-grade glioma in 47 patients
(64%).
Follow-up data at 6 months from baseline are presented in
Table 2. Mean EQ-5D 3 L index value and VAS score at
follow-up did not differ from the baseline scores (p = 0.52
and p = 0.94, respectively). According to the suggested glio-
maMIC value for the EQ-5D 3L index [22], we observed that
14 (19%) improved, 43 (59%) remained unchanged and 16
(22%) deteriorated from the true baseline test.
Using the then-test approach on the entire sample, we
found that the mean EQ-5D 3L index was similar at then-
test compared to baseline (0.77, mean difference 0.01, 95%
CI −0.57 to 0.07, p = 0.82, Fig. 1). Similarly, then-test and
baseline VAS score was compared demonstrating a mean dif-
ference of 0 (95% CI −7 to 7, p = 0.97). Since 30 patients had
been operated on previously, we assessed if there was any
difference in response shift using EQ-5D 3L index between
groups, but there was none (mean difference 0.06, 95% CI
−0.08 to 0.21, p = 0.40). Using the then-test to evaluate
change in relation to MIC, we observed that 21% improved,
54% remained unchanged and 26% deteriorated. Thus, in this
sample of glioma patients, we observed on average no indi-
cation of any statistically significant or clinically relevant re-
sponse shift.
Patients with minimal clinical important change
We found that the 16 patients who reported clinically signifi-
cant deterioration in EQ-5D 3L index at 6 months compared
with true baseline values reported a difference of 0.13 in the
then-test versus true baseline, a result that indicate that their
baseline HRQoL was considered to be worse when scored in
retrospect. However, in these patients the difference between
the true VAS at baseline and the then-test VAS was 0.
When analysing those who improved (n = 14) at 6 months
compared to true baseline, they had a 0.10 difference in then-
test compared to true baseline, with the direction that indicated
that they considered their baseline HRQoL to be better in
retrospect.
Similarly, the VAS score was considered 6 points better in
then-test than at baseline. In Table 3 we also explored the
different EQ-5D 3L domains at then-test compared with base-
line assessment. The findings of EQ-5D 3L index value in the
different MIC groups are visualised in Figs. 2 and 3 to en-
hance interpretation.
Exploratory subgroup analyses of patients with clinically
significant response shift
We used the suggested MIC as guidance in defining patients
who significantly considered their baseline to be better in
Table 1 Baseline characteristics
n = 73
Age in years, mean (SD) 49 (15)
Female, n (%) 26 (36)
Preoperative KPS ≥70, n (%) 70 (96)







Primary surgery, n (%) 43 (59)
Preoperative use of corticosteroids, n (%) 28 (38)
Preoperative tumour volume, median (IQR) 24.2 (5.7–43.9)
Eloquent, n (%) 21 (29)
Resection, n (%) 70 (96)
Histopathology, n (%)
WHO grade II 26 (36)
WHO grade III 19 (26)
WHO grade IV 28 (38)
Extent of resection, median (IQR) 93.2 (81.7–100)
Baseline EQ-5D 3 L index value, mean (SD) 0.78 (0.24)
Baseline EQ-VAS, mean (SD), n = 67 73 (21)
KPS Karnofsky Performance Scale score, CCI Charlson comorbidity in-
dex, Eloquent refers to Sawaya grade 3
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retrospect (n = 18) and those who significantly considered
their baseline to be worse in retrospect (n = 15).
We searched predictors among the variables in Table 1 in
addition to significant surgical complications (Landriel Ibañez
grade 2 or more) or surgically induced neurological deficits.
Of patients who scored their baseline better in retrospect
compared to the rest of the cohort, only seizures at baseline
(61% versus 29%, p = 0.015) and baseline EQ-5D 3L index
value (0.63 versus 0.82, p = 0.003) were factors associated
with significant response shifts.
Of patients who scored their baseline worse in retrospect
compared to the rest of the cohort, only significant surgical
complications was an associated factor (27 versus 3%, p =
0.004).
Discussion
Response-shift assessment of baseline EQ-5D 3L index value
and VAS score at 6 months following surgery for glioma pa-
tients using the then-test approach revealed that in our selec-
tion of patients there was on average no response shift. This
may be due to the fact that the vast majority of our respondents
were clinically stable at follow-up as assessedwith EQ-5D 3L.
Another factor contributing to averaging of results was that we
had almost similar proportion of patients improving (19%)
and deteriorating (22%) in HRQoL at 6 months from baseline.
Response shifts were more frequently observed in both pa-
tients that improved and patients that deteriorated according
to the MIC, but the direction was opposite. Patients that im-
proved had raised their internal standards, while patients that
deteriorated had lowered their internal standards.
Further, we explored possible factors associated with sig-
nificant response shift. A low baseline HRQoL is likely to be
considered better in retrospect according to these exploratory
analyses. This may possibly relate to ceiling effects of generic
HRQoL measures at baseline, where improvement of maxi-
mum score is impossible, or simply due to regression of the
mean [22]. Also, patients with seizures at baseline were over-
represented in the group that reported better baseline HRQoL
in retrospect. These patients are likely to have improved
HRQoL at follow-up due to chance of seizure freedom with
extensive surgery, and therefore now perhaps forgot or re-
pressed how it was living with seizures [4].
As observed by others studying other conditions, response
shift is only present in case of a catalyst [2], and in this regard
it is apparently not enough to be diagnosed with a glioma or
facing repeated surgery due to recurrence, as we only ob-
served response shift in relation to significant changes in
Table 3 How the then-test of EQ-5D domains compare with baseline
assessment
Better Similar Worse
ENTIRE SAMPLE (n = 73)
Then-test mobility (n = 72) 3 67 2
Then-test self-care (n = 72) 2 69 1
Then-test activity (n = 73) 12 50 11
Then-test pain (n = 70) 14 46 10
Then-test anxiety (n = 72) 12 49 11
MIC IMPROVED (n = 14)
Then-test mobility (n = 14) 1 12 1
Then-test self-care (n = 14) 2 11 1
Then-test activity (n = 14) 2 10 2
Then-test pain (n = 14) 2 10 2
Then-test anxiety (n = 14) 7 5 2
UNCHANGED (n = 43)
Then-test mobility (n = 43) 1 42 0
Then-test self-care (n = 43) 0 43 0
Then-test activity (n = 43) 10 26 7
Then-test pain (n = 41) 11 27 3
Then-test anxiety (n = 42) 3 33 6
MIC DETERIORATED (n = 16)
Then-test mobility (n = 15) 1 13 1
Then-test self-care (n = 15) 0 15 0
Then-test activity (n = 16) 0 14 2
Then-test pain (n = 15) 1 9 5
Then-test anxiety (n = 16) 2 11 3
Better in this context refer to that the then-test indicate fewer symptoms/
problems than the baseline assessment
Table 2 Important variables
6 months postoperatively n = 73 Significant change from baseline
6 month KPS ≥70, n (%) 65 (89) p = 0.21
EQ-5D 3 L index value at 6 months, mean (SD) 0.79 (0.21) p = 0.52




VAS score at 6 months, mean (SD), n = 68 72 (17) p = 0.94
MIC minimal clinically important change; the MIC is set to 0.15, as reported by Sagberg and co-workers
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Fig. 3 Response shift seen in
EQ-5D 3L index value in patients
according to groups based on
minimal clinically important
change
Fig. 2 Response shift assessed in
the entire sample (n = 73)
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HRQoL after surgery. However, we observe that significant
complications triggered a response shift in terms of consider-
ing the baseline HRQoL worse in retrospect, reducing the
negative impact on HRQoL from the surgical complications
6 months after surgery.
As seen above, the direction of response shift in our
study suggests that response shift may reduce the actual
changes seen in longitudinal HRQoL studies, with re-
spect to both deterioration and improvement, when
using EQ-5D 3L index value according to the then-test
model [25]. One practical implication this has for inter-
pretation is that glioma patients who remain stable after
surgery according to MIC groups are not stable simply
due to response shift since we did not observe any
response shift in this stable group. Further, for glioma
patients with significant changes in HRQoL after sur-
gery, they seemingly more frequently recalibrate their
internal standards, reducing the actual effect size of
the change as observed in longitudinal studies.
Our study was not designed to evaluate the relative impor-
tance of the different elements of response shift (i.e. recalibra-
tion, reprioritisation and reconceptualisation). In a recent
study of patients with prostate cancer, reconceptualisation
was not an important factor, perhaps indicating that the other
two are more important elements in response shift among
cancer patients [8]. Others consider the elements of
reprioritisation and reconceptualisation not to be a true re-
sponse shift, but rather coping strategies affecting the true
value [3]. In this view, recalibration is the only true response
shift.
The underlying assumptions of the then-test used in
this study have recently been criticised [27]. Most im-
portantly, the assumption of cognitive consistency of
respondents at the different time points may not hold
true [27]. Also, recall bias of previous health condition
is a concern [25, 27], especially since this may be more
pronounced in patients with cognitive deficits [1]. In
our study, all patients were able to complete the then-
test, but many were naturally cognitively impaired. This
may contribute to the rather wide confidence intervals
observed in this study [3]. Even though global HRQoL
has been found to have among the larger effect sizes,
generic HRQoL measures are in general less sensitive
and this may have contributed to the group level results
in our study [25]. Also, since response shift assessments
require patients that are able to report their own health
state at both baseline and at follow-up, thus terminally
ill patients, patients with severe cognitive deficits or
patients with severe language problems were not includ-
ed in this study. Consequently, the interpretation of our
results must be understood in the light of the selection
reported in Fig. 1, where an unavoidable selection bias
seems to be present which may influence our results.
Finally, in the light of the above-mentioned limitations
and since this is the first paper to assess response shift
after glioma surgery caution is needed when interpreting
our results, and especially the more exploratory findings
should be considered hypothesis-generating.
This study is important for the interpretation of our
earlier studies using EQ-5D 3L in gliomas [7, 12–15,
22, 23]. Most importantly, we are now more confident
that it is not a response-shift artefact when patients report-
ed stable HRQoL. It is perhaps comforting that the re-
sponse shift may reduce the negative effect of glioma
surgery or disease progression, but we should not accept
that patients reduce their standards if this can be avoided
with either safer surgery or more effective treatment
delaying time to progression. Thus, we should continue
to evaluate our results and readjusting our practice if this
improves the onco-functional balance [20].
Conclusions
Our results indicate that response shift in glioma pa-
tients undergoing surgery is dependent on changes in
HRQoL at time of assessment. Importantly, patients
reporting stable HRQoL at follow-up demonstrated no
response shift in our study. Further, response shift
seems to reduce the effects of HRQoL changes by low-
ering of internal standards in patients that deteriorate
and raising the standards in patients that improve.
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